144.550 -

-0.440 (-0.30%)
Range 142.679 - 146.130   (2.42%)
Open 144.230
Previous Close 144.990
Bid Price 144.470
Bid Volume 101
Ask Price 144.610
Ask Volume 4
Volume 918,134
Value 100,931,021
Remark -
Delayed prices. Updated at 16 Mar 2026 22:35.
Data powered by
View All Events

About Gilead Sciences

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

There are 11 followers

Pen
Followers
4
I'm just going to share my INV thoughts and reading notes here
Followers
47
Followers
1
Followers
0
Followers
0
Followers
0
FOUNDER, SGSTOCKSINVESTING.COM
Followers
773
Followers
0
Followers
0
Followers
2
Followers
68